Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $60
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating
Corbus Pharmaceuticals (CRBP) Receives a Buy From Mizuho Securities
Express News | Corbus Pharmaceuticals Holdings Inc - First Data From Dose Escalation Expected in Q1 2025
Express News | Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (Crb-701)
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)